USC Norris Comprehensive Cancer Center

Running trials

• Recruiting

  Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation

  NCT07615049· Phase 3· SWOG Cancer Research Network· Source

• Not yet recruiting

  Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer

  NCT07836712· Phase 2· University of Southern California· Source

• Not yet recruiting

  Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older

  NCT07838974· Phase 1· University of Southern California· Source

• Recruiting

  A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  NCT07293247· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Not yet recruiting

  A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

  NCT07814417· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

  NCT07441681· Phase 3· NRG Oncology· Source

• Recruiting

  Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

  NCT07452458· Phase 3· NRG Oncology· Source

• Recruiting

  A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

  NCT07309445· Janssen Research & Development, LLC· Source

• Recruiting

  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  NCT07504458· Phase 3· Quetzal Therapeutics· Source

• Not yet recruiting

  Social Determinants of Health HCC Trial

  NCT07568457· University of Southern California· Source

• Recruiting

  Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  NCT06980038· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Indian and Alaska Native Cancer Patients Living in Rural California

  NCT07332312· University of Southern California· Source

• Recruiting

  Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

  NCT07219459· Phase 2· CatalYm GmbH· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

  NCT07339254· University of Southern California· Source

• Recruiting

  A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

  NCT07337525· Phase 1· Pilatus Biosciences Inc· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  NCT07397338· Phase 1/2· Revolution Medicines, Inc.· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· Phase 3· IDEAYA Biosciences· Source

• Active, not recruiting

  AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

  NCT07285694· Phase 1/2· Arsenal Biosciences, Inc.· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

  NCT07104565· Phase 2· Incyte Corporation· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

  NCT07265947· Phase 2· Tyra Biosciences, Inc· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source

• Recruiting

  Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  NCT07227012· Phase 1/2· Pfizer· Source

• Recruiting

  A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  NCT07227402· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

  NCT07217171· Phase 1· EvolveImmune United, Inc· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  NCT07007962· Phase 3· Sanofi· Source

• Recruiting

  Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

  NCT07246863· Phase 2· CatalYm GmbH· Source

• Recruiting

  Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD

  NCT07186699· University of Southern California· Source

• Recruiting

  MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial

  NCT07162194· University of Southern California· Source

• Recruiting

  A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

  NCT07037758· Phase 1· Amgen· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Active, not recruiting

  CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

  NCT06730100· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

  NCT07023289· Phase 2· AbbVie· Source

• Recruiting

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· Phase 1/2· Alentis Therapeutics AG· Source

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Disc Medicine, Inc· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07005102· Phase 2/3· AbbVie· Source

• Recruiting

  Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

  NCT07098988· Phase 2· CatalYm GmbH· Source

• Recruiting

  A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

  NCT06721013· Phase 1/2· Eli Lilly and Company· Source

Showing 50 of 332.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer30 recruiting
• Colorectal cancer24 recruiting
• Bladder cancer16 recruiting
• Liver and biliary tract cancer15 recruiting
• Prostate cancer15 recruiting
• Head and neck cancer14 recruiting
• Melanoma14 recruiting
• Gastric and oesophageal cancer11 recruiting
• Ovarian cancer11 recruiting
• Kidney cancer10 recruiting
• Pancreatic cancer9 recruiting
• Childhood cancers8 recruiting
• Sarcoma8 recruiting
• Triple-negative breast cancer8 recruiting
• Acute myeloid leukaemia6 recruiting
• Immune thrombocytopenia (ITP)6 recruiting
• Metastatic breast cancer5 recruiting
• Endometrial cancer4 recruiting
• Neuroendocrine tumours4 recruiting
• Cervical cancer2 recruiting
• Glioblastoma2 recruiting
• Mesothelioma2 recruiting
• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Completed

  Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

  NCT06665308· Sanofi· Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· Phase 1· BeOne Medicines· Source

• Terminated

  A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

  NCT06523803· Phase 1· Zymeworks BC Inc.· Source

• Completed

  A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers

  NCT06345001· Phase 1· Bayer· Source

• Terminated

  A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

  NCT06336148· Phase 1· Actym Therapeutics, Inc.· Source

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Phase 1· Deciphera Pharmaceuticals, LLC· Source

• Terminated

  NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

  NCT06299163· Phase 1· Numab Therapeutics AG· Source

• Terminated

  FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

  NCT06338657· Phase 1· University of Southern California· Source

• Withdrawn

  Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

  NCT05743270· Phase 2· Replimune, Inc.· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Polaris Group· Source

• Terminated

  IMM60 and Pembrolizumab in Melanoma and NSCLC

  NCT05709821· Phase 1/2· iOx Therapeutics· Source

• Completed

  Prostate Resection After Microwave Ablation (PRAMA)

  NCT06128525· University of Southern California· Source

• Terminated

  Study of ALE.C04 in Patients With Head and Neck Cancer

  NCT06054477· Phase 1/2· Alentis Therapeutics AG· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Ferring Pharmaceuticals· Source

• Withdrawn

  sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

  NCT03552796· Phase 1· University of Southern California· Source

• Terminated

  RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

  NCT05733611· Phase 2· Replimune, Inc.· Source

• Completed

  A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

  NCT05630183· Phase 2· Agenus Inc.· Source

• Terminated

  ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

  NCT05743036· Phase 1· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source

• Terminated

  A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

  NCT05336409· Phase 1· Century Therapeutics, Inc.· Source

• Completed

  A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05271604· Phase 2· BioAtla, Inc.· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Completed

  Study of DF9001 in Patients With Advanced Solid Tumors

  NCT05597839· Phase 1/2· Dragonfly Therapeutics· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  Nirogacestat in Ovarian Granulosa Cell Tumors

  NCT05348356· Phase 2· SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  NCT05548296· Phase 2· Acrivon Therapeutics· Source

• Terminated

  Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

  NCT05353439· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

  NCT04712877· Lung Cancer Mutation Consortium· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Incyte Corporation· Source

• Terminated

  A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

  NCT05229601· Phase 1· HiFiBiO Therapeutics· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Coherus Oncology, Inc.· Source

• Completed

  Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

  NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source

• Terminated

  Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

  NCT04221438· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

  NCT04530552· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Terminated

  7T MRI Scan for the Early Detection of Melanoma Brain Metastases

  NCT04941430· University of Southern California· Source

• Terminated

  Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

  NCT03698162· University of Southern California· Source

• Completed

  INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

  NCT04455841· Phase 1/2· Incyte Corporation· Source

• Completed

  A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

  NCT05230186· TScan Therapeutics, Inc.· Source

• Terminated

  CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  NCT04695977· Phase 2/3· Regeneron Pharmaceuticals· Source

• Terminated

  CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT04633278· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

  NCT04631445· Translational Drug Development· Source

• Completed

  Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

  NCT03641313· Phase 2· National Cancer Institute (NCI)· Source

• Terminated

  Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· Phase 1/2· Pfizer· Source

• Completed

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· Phase 1/2· Elevar Therapeutics· Source

• Completed

  Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

  NCT04374877· Phase 1· Coherus Oncology, Inc.· Source

• Terminated

  Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

  NCT03765736· Academic and Community Cancer Research United· Source

• Completed

  Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

  NCT04160065· Phase 1· TuHURA Biosciences, Inc.· Source

• Terminated

  Fluid Biopsy for the Diagnosis of Lung Cancer

  NCT04162678· University of Southern California· Source

Showing 50 of 108.

Conditions

Diseases this institution publishes on or runs trials for.

• Colorectal cancer78 works · 65 trials
• Bladder cancer43 works · 44 trials
• Acute lymphoblastic leukaemia13 works · 4 trials